Table 2. Standardised incidence ratio (SIR) and absolute excess risk (AER) for all second cancers diagnosed in 1972–2003 following BCIS (breast carcinoma in situ) in southern Netherlands.
|
Relative and absolute risksa
|
|||||
|---|---|---|---|---|---|
| Site of second cancer | Observed | Expected | SIR | 95% CI | AER |
| All sites | 113 | 54.4 | 2.1b | 1.7–2.5 | 90 |
| All sites excluding breastc | 52 | 36.2 | 1.4b | 1.1–1.9 | 24 |
| Digestive tract d | 11 | 10.4 | 1.1 | 0.5–1.9 | 1 |
| Stomach | 3 | 1.6 | 1.8 | 0.4–5.3 | 2 |
| Colon | 6 | 5.2 | 1.2 | 0.4–2.5 | 1 |
| Lung | 5 | 3.5 | 1.4 | 0.5–3.3 | 2 |
| Skin e | 27 | 15.8 | 1.7b | 1.1–2.5 | 17 |
| Melanoma | 4 | 1.4 | 3.0 | 0.8–7.6 | 4 |
| Basal cell carcinoma | 22 | 12.8 | 1.7b | 1.1–2.6 | 14 |
| Breast | 61 | 18.1 | 3.4b | 2.6–4.3 | 66 |
| Ipsilateralf | 29 | 15.5 | 1.9b | 1.3–2.7 | 24 |
| Contralateralf | 31 | 15.5 | 2.0b | 1.4–2.8 | 28 |
| Urogenital tract g | 4 | 7.1 | 0.6 | 0.2–1.4 | −5 |
| Ovary | 2 | 2.5 | 0.8 | 0.1–2.8 | −1 |
| Lymphoma and multiple myeloma | 2 | 2.5 | 0.8 | 0.1–2.9 | −1 |
a
Excluding patients with less than 1-year follow-up.
b
95% confidence interval excludes 1.
c
Three observed are primary cancers of unknown origin.
d
Also includes pancreas [1] and rectum [1].
e
Also includes squamous cell carcinoma of the skin [1]
f
Only includes patients with known laterality of BCIS and second breast cancer.
g
Also includes corpus uteri [1] and bladder [1].